Observational studyDiseases of the esophagus : official journal of the International Society for Diseases of the Esophagus2026
Incidence of lymph node metastases in pT1 chemo- and radiotherapy-naïve esophageal and gastric cancer in the Nordic countries: a retrospective multinational cohort analysis.
Observational study in Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although endoscopic resection is reported to be safe for early-stage esophagogastric cancer, uncertainty remains regarding oncological efficacy, particularly for submucosal lesions. The aim of this study was to assess the frequency of lymph node metastasis (LNM) and survival in patients operated for chemo- and radiotherapy-naïve pT1 esophagogastric cancer. Patients who underwent surgical resection for esophageal or gastric pT1 adenocarcinoma or squamous cell carcinoma without neoadjuvant oncologic treatment were included. Data were retrospectively extracted from registries in Denmark (2013-2021), Norway (2007-2024), Sweden (2012-2022), and Finland (2000-2016). The primary outcome was the frequency of LNM in resected specimens from patients operated for pT1 esophagogastric cancer. Secondary outcomes included: 5-year overall survival, number of lymph nodes harvested, and risk factors associated with LNM and mortality. 1647 patients with pT1 tumors were identified, of whom 949 (58%) did not receive neoadjuvant treatment; 413 (43%) had esophagectomy and 536 (56%) gastrectomy. 145 (15%) patients had LNM identified in the resected specimens for esophagectomies, the LNM rate was 3% for pT1a and 20% for pT1b, and for gastrectomies, 7% for pT1a and 21% for pT1b. The median follow-up was 62 months (interquartile range: 33-102) and 5-year overall survival was 81% for patients with pT1a tumors and 65% for those with pT1b tumors. Among patients with pT1b, the overall survival was 69% without LNM and 51% with LNM. Depth of tumor invasion was associated with risk of LNM. A high proportion of patients had LNM after resection for chemo- and radiotherapy-naïve pT1 esophagogastric cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.